Hypertrophic Scars
Conditions
Keywords
fractional laser, hypertrophic scar, topical corticosteroid, laser assisted delivery systems
Brief summary
The objective of this study is to evaluate the efficacy and safety of using ablative fractional laser- assisted topical corticosteroid delivery for the treatment of hypertrophic scar.
Detailed description
Hypertrophic scars are common conditions that cause persistent symptom and can lead to severe psychosocial impairment. Intralesional corticosteroid have been a mainstay in the treatment of hypertrophic scars. However, there are many disadvantages of corticosteroid injection such as severe pain, skin atrophy, skin thinning, steroid acne, telangiectasia and hypopigmentation. Recent reports propose new treatment methods for hypertrophic scars with the use of fractional ablative lasers to create zones of ablation of the skin that may assisted the penetration of drugs to the skin.
Interventions
0.05% Clobetasol propionate was rubbed for 2 minutes on one side of the scar immediately after treated with fractional Erbium: YAG (2,940-nm) laser. The treatment was done in every 2 weeks for 4 sessions
DRUGPetrolatum gel
Petrolatum gel was rubbed for 2 minutes on the other side of the scar immediately after treated with fractional Erbium: YAG (2,940-nm) laser.The treatment was done in every 2 weeks for 4 sessions
DEVICEFractional Erbium:Yag (2,940-nm) laser
The parameter of the laser was 28 J/cm2, 5% spot density, 1 pass for the whole scar. The treatment was done in every 2 weeks for 4 sessions
Sponsors
Mahidol University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Female subjects with age range 18-60 years; * Subject with hypertrophic scar from abdominal surgery for at least 3 months; * Discontinued using oral isotretinoin for 6 months, alpha hydroxy acid or topical retinoic acid for 3 months
Exclusion criteria
* Subject who has skin Infection, photosensitive dermatosis or inflammatory acne on the treated area; * Subject who smoke cigarette; * Subject who was treated with Intralesional corticosteroid
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Scar thickness measured by digital calliper | change from baseline in scar thickness at 6 months |
Secondary
| Measure | Time frame |
|---|---|
| Patient and observer scar assessment scale | Baseline, 1 month after first treatment, 1,3 and 6 months after fourth treatment |
Countries
Thailand
Outcome results
None listed